Sinovac Biotech Ltd. Stock

Equities

SVA

AGP8696W1045

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2019-02-22 pm EST 5-day change 1st Jan Change
6.47 USD -0.31% Intraday chart for Sinovac Biotech Ltd. -.--% -.--%
Sales 2022 1.49B Sales 2023 448M Capitalization 642M
Net income 2022 114M Net income 2023 -99M EV / Sales 2022 -7.1 x
Net cash position 2022 11.24B Net cash position 2023 10.92B EV / Sales 2023 -22.9 x
P/E ratio 2022
6.49 x
P/E ratio 2023
-6.09 x
Employees 3,037
Yield 2022 *
-
Yield 2023
-
Free-Float 67.54%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 60 03-08-31
Director of Finance/CFO 57 -
Chief Operating Officer 47 16-03-31
Members of the board TitleAgeSince
Director/Board Member 62 04-06-30
Chief Executive Officer 60 03-08-31
Director/Board Member 55 11-05-30
More insiders
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
More about the company